Is Kerendia Approved for Diabetes?
Kerendia (finerenone) is approved to reduce kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease (CKD) associated with type 2 diabetes.[1] It targets CKD in this specific population, not diabetes itself.
How Does Kerendia Fit into Diabetes Treatment?
Finerenone is a non-steroidal mineralocorticoid receptor antagonist that lowers albuminuria and slows CKD progression in type 2 diabetes patients, based on the FIDELIO-DKD and FIGARO-DKD trials showing cardiovascular and renal benefits.[1][2] It's added to standard care like ACE inhibitors or ARBs, but guidelines do not list it as primary diabetes therapy—focus remains on glucose control with drugs like metformin, SGLT2 inhibitors, or GLP-1 agonists.
When Do Doctors Prescribe It for Diabetes Patients?
Prescribed for type 2 diabetes patients with CKD (eGFR 25-75 mL/min/1.73m², elevated albuminuria), often alongside persistent risk despite other treatments.[1] Not for type 1 diabetes or diabetes without CKD. Bayer markets it for this high-risk group to address cardiorenal complications.
What Are Common Side Effects in Diabetes Patients?
Hyperkalemia (high potassium) occurs in 14% of users vs. 7% placebo, requiring monitoring; other risks include hypotension and creatinine rises.[1] Diabetes patients on RAAS inhibitors face higher hyperkalemia risk, so regular labs are standard.
How Does Kerendia Compare to Other Diabetes Kidney Protectors?
Unlike SGLT2 inhibitors (e.g., Farxiga, approved for broader CKD/diabetes use with stronger glucose-lowering), Kerendia focuses on mineralocorticoid blockade without affecting blood sugar.[2] GLP-1s like Ozempic add weight loss benefits. Combination use is common in guidelines for additive protection.
When Does Kerendia's Patent Expire?
U.S. patents for finerenone extend to 2030, with pediatric exclusivity to 2031; challenges from generics are pending but no approvals yet.3
[1]: https://www.kerendia.com/ (official site, FDA label summary)
[2]: https://www.nejm.org/doi/full/10.1056/NEJMoa2025845 (FIDELIO-DKD trial)